Skip to content

Study · Randomized controlled trial · n = 145 · 2012

3 results

Lanreotide Autogel 90 mg and lymphorrhea prevention after axillary node dissection in breast cancer: a phase III double blind, randomized, placebo-controlled trial.

Gauthier T, Garuchet-Bigot A, Marin B, Mollard J, Loum O, Fermeaux V, Jammet I, Kanoun D, Maubon A, Aubard Y

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology15 Jun 2012Cited by 10 (Europe PMC)

PMID22703757 (opens in a new tab)DOI10.1016/j.ejso.2012.05.009 (opens in a new tab)PepBankPUB-22703757
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    After axillary dissection, lymphorrhea with lanreotide versus placebo was median 292 ml (range 1-965) versus 337 ml (range 0-1230), p = 0.18.

    In plain wordsAfter breast cancer surgery, lanreotide did not significantly reduce lymph fluid volume versus placebo.

    Peptide
    Lanreotide
    Outcome
    No significant changeLymphorrhea volume at four days
    Study

    n = 145

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    90 mgAs given in this study (human).

    Measurements

    Median lymphorrhea volume
    292 ml
    lanreotide group, first four postoperative days
    Range of lymphorrhea volume
    1 to 965 ml
    lanreotide group, first four postoperative days
    Median lymphorrhea volume
    337 ml
    placebo group, first four postoperative days
    Range of lymphorrhea volume
    0 to 1230 ml
    placebo group, first four postoperative days
    P value
    0.18 P
    lanreotide versus placebo

    Source sentences

    Summary
    At four postoperative days, there was a tendency towards a reduction of the lymphorrhea volume in the lanreotide group (median 292 ml, range 1-965 ml) as compared to the placebo group (median 337 ml, range 0-1230 ml), although it was not statistically significant (p = 0.18).
    2 context sentences
    Summary · context
    A Phase III double-blind, randomized, placebo-controlled trial was performed between April 1st, 2008, and December 31st, 2010.
    Summary · context
    On the day before surgery 73 patients received the placebo and 72 patients received lanreotide.
  2. 02HumanRandomized controlled trialEfficacy outcome

    Lanreotide and placebo did not significantly differ in drain removal time, hospital stay, later lymphorrhea, seroma aspirations, wound assessment, arm pain, or mobility.

    In plain wordsAfter breast cancer surgery, lanreotide did not significantly change the secondary outcomes versus placebo.

    Peptide
    Lanreotide
    Outcome
    No significant changeSecondary endpoints
    Study

    n = 145

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    90 mgAs given in this study (human).

    Source sentences

    Summary
    There was no significant difference for the secondary end points.
    4 context sentences
    Summary · context
    The secondary end points were the number of days until axillary drain removal, hospital stay duration (days), lymphorrhea volume (ml) up to days 15, 30 and 180, number of cases with seroma aspiration and number of seroma aspirations,
    Summary · context
    evaluation of wound, arm pain and mobility on days 15, 30 and 180.
    Summary · context
    A Phase III double-blind, randomized, placebo-controlled trial was performed between April 1st, 2008, and December 31st, 2010.
    Summary · context
    On the day before surgery 73 patients received the placebo and 72 patients received lanreotide.
  3. 03HumanObservational studyEfficacy outcome

    In a subgroup of patients with axillary dissection alone (n = 24), lymphorrhea volume was significantly lower with lanreotide than with placebo, p = 0.035.

    In plain wordsIn a subgroup having axillary dissection alone, lanreotide reduced lymph fluid volume versus placebo.

    Peptide
    Lanreotide
    Outcome
    DecreaseLymphorrhea volume after axillary dissection alone
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    90 mgAs given in this study (human).

    Measurements

    P value, lanreotide vs placebo
    0.035 p
    axillary dissection alone subgroup

    Source sentences

    Summary
    In the group with axillary dissection performed alone (n = 24), the lymphorrhea volume was shown to be significantly reduced in the lanreotide group, (p = 0.035) as compared to the placebo group.
    2 context sentences
    Summary · context
    A Phase III double-blind, randomized, placebo-controlled trial was performed between April 1st, 2008, and December 31st, 2010.
    Summary · context
    On the day before surgery 73 patients received the placebo and 72 patients received lanreotide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.